JP2024546996A5 - - Google Patents
Info
- Publication number
- JP2024546996A5 JP2024546996A5 JP2024536163A JP2024536163A JP2024546996A5 JP 2024546996 A5 JP2024546996 A5 JP 2024546996A5 JP 2024536163 A JP2024536163 A JP 2024536163A JP 2024536163 A JP2024536163 A JP 2024536163A JP 2024546996 A5 JP2024546996 A5 JP 2024546996A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- isoform
- vlcdr1
- vlcdr2
- vlcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21215028.8 | 2021-12-16 | ||
| EP21215028 | 2021-12-16 | ||
| EP22164796.9 | 2022-03-28 | ||
| EP22164796 | 2022-03-28 | ||
| EP22207926 | 2022-11-16 | ||
| EP22207926.1 | 2022-11-16 | ||
| PCT/EP2022/086452 WO2023111311A1 (en) | 2021-12-16 | 2022-12-16 | Discernible cell surface protein variants of cd117 for use in cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546996A JP2024546996A (ja) | 2024-12-26 |
| JP2024546996A5 true JP2024546996A5 (cg-RX-API-DMAC7.html) | 2025-12-23 |
Family
ID=84981434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536163A Pending JP2024546996A (ja) | 2021-12-16 | 2022-12-16 | 細胞療法に使用するためのcd117の識別可能な細胞表面タンパク質変異体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250057951A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4448573A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546996A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240115920A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022409748A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3240527A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313568A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007317A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023111311A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202405110B (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4540287A1 (en) * | 2022-06-20 | 2025-04-23 | CRISPR Therapeutics AG | Chimeric antigen receptor specific to cd117 |
| EP4543469A4 (en) * | 2022-06-27 | 2026-06-03 | Beam Therapeutics Inc | COMPOSITIONS AND CONDITIONING METHODS OF NON-GENOTOXIC CELLS |
| EP4551601A1 (en) * | 2022-07-07 | 2025-05-14 | Cimeio Therapeutics AG | Antibodies targeting cd117 |
| WO2025231071A1 (en) * | 2024-05-01 | 2025-11-06 | Beam Therapeutics Inc. | Compositions and methods for cell conditioning |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0578774T3 (da) | 1991-04-05 | 1999-04-26 | Univ Washington | Monoklonale antistoffer mod stamcellefaktor-receptorer |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之c-kit抗體 |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| EP3448995A1 (en) | 2016-04-25 | 2019-03-06 | Universität Basel | Allele editing and applications thereof |
| US20190365806A1 (en) | 2016-11-02 | 2019-12-05 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| US10882915B2 (en) * | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| EP3700568A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| CN113164570B (zh) * | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| UA128431C2 (uk) | 2018-11-26 | 2024-07-10 | Форті Севен, Інк. | ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit |
| JP2022529727A (ja) * | 2019-04-24 | 2022-06-23 | マジェンタ セラピューティクス インコーポレイテッド | Anti-cd117 とその使用 |
| AU2020336969B2 (en) | 2019-08-29 | 2024-12-05 | Beam Therapeutics Inc. | Compositions and methods for non-toxic conditioning |
-
2022
- 2022-12-16 IL IL313568A patent/IL313568A/en unknown
- 2022-12-16 CA CA3240527A patent/CA3240527A1/en active Pending
- 2022-12-16 US US18/719,780 patent/US20250057951A1/en active Pending
- 2022-12-16 JP JP2024536163A patent/JP2024546996A/ja active Pending
- 2022-12-16 MX MX2024007317A patent/MX2024007317A/es unknown
- 2022-12-16 EP EP22843648.1A patent/EP4448573A1/en active Pending
- 2022-12-16 WO PCT/EP2022/086452 patent/WO2023111311A1/en not_active Ceased
- 2022-12-16 AU AU2022409748A patent/AU2022409748A1/en active Pending
- 2022-12-16 KR KR1020247023745A patent/KR20240115920A/ko active Pending
-
2024
- 2024-06-28 ZA ZA2024/05110A patent/ZA202405110B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6993699B2 (ja) | ヒトインターロイキン-2に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質 | |
| EP2788379B1 (en) | Pdgf receptor beta binding polypeptides | |
| CN114341189A (zh) | 全新il-15前药及其应用 | |
| ES2774422T3 (es) | Anticuerpos para IL-21 | |
| WO2021062406A1 (en) | Cytokine prodrugs and dual-prodrugs | |
| WO2019080872A1 (zh) | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 | |
| EP4192872B1 (en) | Proteins binding nkg2d, cd16 and egfr | |
| CN116323671A (zh) | 具有增加的选择性的多靶向性双特异性抗原结合分子 | |
| JP2017535257A (ja) | 免疫応答およびがん治療の増強に使用するための組成物および方法 | |
| JP7855521B2 (ja) | ヒト抗cd33抗体及びその使用 | |
| WO2020168555A1 (zh) | Cd3抗原结合片段及其应用 | |
| TW202110894A (zh) | 抗alk2抗體 | |
| TW202607029A (zh) | 三特異性結合蛋白、方法及其用途 | |
| JP2021508247A (ja) | 抗フリズルド抗体及び使用方法 | |
| TW201520226A (zh) | 泛-elr+cxc趨化因子抗體 | |
| CN116323667A (zh) | 结合PSMA和γ-δT细胞受体的抗体 | |
| WO2022223001A1 (zh) | 双特异性多功能融合多肽 | |
| WO2023020537A1 (zh) | 一种双特异性抗体及其用途 | |
| TW202440636A (zh) | Cd19/cd38多特異性抗體 | |
| TW202102544A (zh) | 雙特異性抗體 | |
| JP2025500288A5 (cg-RX-API-DMAC7.html) | ||
| KR20180021875A (ko) | 다중특이적 결합 단백질 | |
| US20250313644A1 (en) | Antibodies capable of specifically binding tl1a and use thereof | |
| JP7849919B2 (ja) | ヒトdr3に特異的に結合する抗体及びその用途 | |
| JP2019505516A (ja) | インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法 |